Premium
Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide in children and adolescents with hematological malignancies
Author(s) -
GonzálezLlano Oscar,
GonzálezLópez Elías Eugenio,
RamírezCázares Ana Carolina,
MarcosRamírez Edson René,
RuizArgüelles Guillermo José,
GómezAlmaguer David
Publication year - 2016
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26131
Subject(s) - medicine , cumulative incidence , hematopoietic stem cell transplantation , cyclophosphamide , transplantation , incidence (geometry) , graft versus host disease , retrospective cohort study , stem cell , oncology , chemotherapy , physics , biology , optics , genetics
Background Haploidentical hematopoietic stem cell transplantation (haplo‐HSCT) using posttransplant cyclophosphamide (Cy) for graft versus host disease (GVHD) prophylaxis has emerged as an alternative transplant strategy for patients without related donors, especially in the setting of limited resources in which T‐cell ex vivo depletion is not affordable. Experience with this transplant modality in children and adolescents is limited. Procedure We report a retrospective analysis of 25 consecutive outpatients under 21 years of age with high‐risk hematological malignancies, who received a haplo‐HSCT using posttransplant Cy as GVHD prophylaxis. Results Twenty‐three (92%) of the 25 patients engrafted, and 20 (95%) of 21 evaluable subjects achieved full donor chimerism by day +30. One‐year estimated overall survival and event‐free survival were 50% and 33%, respectively. The cumulative incidence rate of severe acute GVHD was 19%, and 15% of patients developed chronic GVHD. Conclusions Haplo‐HSCT with posttransplant Cy is a feasible therapeutic option for children and adolescents with high‐risk hematological malignancies in a limited resource setting.